Cutting edge: C1q protects against the development of glomerulonephritis independently of C3 activation
- PMID: 10229798
Cutting edge: C1q protects against the development of glomerulonephritis independently of C3 activation
Abstract
C1q-deficient (C1qa-/-) mice develop antinuclear Abs and glomerulonephritis (GN) characterized by multiple apoptotic bodies. To explore the contribution of C3 activation to the induction of spontaneous GN, C1qa-/- mice were crossed with factor B- and C2-deficient (H2-Bf/C2-/-) mice. GN was present in 64% of the 45 C1qa/H2-Bf/C2-/- mice compared with 8% of the 65 H2-Bf/C2-/- mice and none of the 24 wild-type controls. IgG was detected in the glomeruli of diseased C1qa/H2-Bf/C2-/- kidneys. However, glomerular staining for C3 was absent. Increased numbers of glomerular apoptotic bodies were detected in undiseased C1qa/H2-Bf/C2-/- kidneys. These findings support the hypothesis that C1q may play a role in the clearance of apoptotic cells without the necessity for C3 activation and demonstrate that the activation of C3 is not essential for the development of GN in this spontaneous model of lupus-like disease.
Similar articles
-
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies.Nat Genet. 1998 May;19(1):56-9. doi: 10.1038/ng0598-56. Nat Genet. 1998. PMID: 9590289
-
Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient mice.J Immunol. 2001 Jun 1;166(11):6820-8. doi: 10.4049/jimmunol.166.11.6820. J Immunol. 2001. PMID: 11359841
-
Increased susceptibility of complement factor B/C2 double knockout mice and mannan-binding lectin knockout mice to systemic infection with Candida albicans.Mol Immunol. 2008 Sep;45(15):3934-41. doi: 10.1016/j.molimm.2008.06.021. Epub 2008 Jul 30. Mol Immunol. 2008. PMID: 18672286
-
Classical pathway deficiencies - A short analytical review.Mol Immunol. 2015 Nov;68(1):14-9. doi: 10.1016/j.molimm.2015.05.007. Epub 2015 May 30. Mol Immunol. 2015. PMID: 26038300 Review.
-
The role of the alternative pathway of complement activation in glomerular diseases.Clin Exp Med. 2018 Aug;18(3):297-318. doi: 10.1007/s10238-018-0491-8. Epub 2018 Feb 15. Clin Exp Med. 2018. PMID: 29450785 Review.
Cited by
-
IgM antibodies to apoptosis-associated determinants recruit C1q and enhance dendritic cell phagocytosis of apoptotic cells.J Immunol. 2009 May 15;182(10):6031-43. doi: 10.4049/jimmunol.0804191. J Immunol. 2009. PMID: 19414754 Free PMC article.
-
Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2.J Exp Med. 2000 Nov 6;192(9):1339-52. doi: 10.1084/jem.192.9.1339. J Exp Med. 2000. PMID: 11067882 Free PMC article.
-
The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activation.Auto Immun Highlights. 2016 Dec;7(1):6. doi: 10.1007/s13317-016-0078-x. Epub 2016 Mar 3. Auto Immun Highlights. 2016. PMID: 26935316 Free PMC article.
-
Apoptosis and autoimmunity: complement deficiency and systemic lupus erythematosus revisited.Curr Rheumatol Rep. 2000 Feb;2(1):32-8. doi: 10.1007/s11926-996-0066-7. Curr Rheumatol Rep. 2000. PMID: 11123037 Review.
-
Targeting the Immune Complex-Bound Complement C3d Ligand as a Novel Therapy for Lupus.J Immunol. 2019 Dec 15;203(12):3136-3147. doi: 10.4049/jimmunol.1900620. Epub 2019 Nov 15. J Immunol. 2019. PMID: 31732528 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Molecular Biology Databases
Miscellaneous